Showing 2731-2740 of 5300 results for "".
Understanding the MOA of NEMLUVIO®: Targeting IL-31 Signaling in Neuroimmune Skin Diseases
https://practicaldermatology.com/programs/nemluvio-peer-network/understanding-the-moa-of-nemluvio-targeting-il-31-signaling-in-neuroimmune-skin-diseases/37128/Watch Dr Peter Lio as he explains the role of IL-31, a key neuroimmune cytokine, in AD and PN and provides an in depth overview of the mechanism of action for NEMLUVIO®.How NEMLUVIO® Works
https://practicaldermatology.com/programs/nemluvio-peer-network/how-nemluvio-works/37226/Learn how NEMLUVIO® works to directly block IL-31RA from Dr Peter Lio, a leading dermatologist, with extensive experience in treating neuroimmune skin diseases.Remaking Ourselves: Aesthetic Medicine That Is Regenerative
https://practicaldermatology.com/issues/october-2025/remaking-ourselves-aesthetic-medicine-that-is-regenerative/39752/Preparing for Private Equity: Benefits and Drawbacks
https://practicaldermatology.com/issues/september-2025/preparing-for-private-equity-benefits-and-drawbacks/37629/Over the past decade, the health care industry has emerged as a prime target for private equity (PE) investment.Dermatology Recruitment in the Age of Private Equity
https://practicaldermatology.com/issues/september-2025/dermatology-recruitment-in-the-age-of-private-equity/37638/A recruiting executive offers a balanced view from the fieldMergers and Acquisitions in Derm and Aesthetics: Market Outlook
https://practicaldermatology.com/issues/september-2025/mergers-and-acquisitions-in-derm-and-aesthetics-market-outlook/37631/We took a deeper look into the dermatology and aesthetics mergers and acquisitions (M&A) market in a conversation with two of our team members, Drew Thomas and Jordan Frickle, who are closely involved in this sector. The following discussion brings together their perspectives on current trends,Busy by Design Plans: How to Use Downtime to Drive Revenue and Make Uptime Smoother for Your Team
https://practicaldermatology.com/issues/september-2025/busy-by-design-plans-how-to-use-downtime-to-drive-revenue-and-make-uptime-smoother-for-your-team/37641/In today’s fast-paced dermatology industry, treatments can sometimes feel more transactional than transformational.Dr. DiAnne Davis on Mentorship, Lasers, Skin of Color, and More
https://practicaldermatology.com/issues/september-2025/dr-dianne-davis-on-mentorship-lasers-skin-of-color-and-more/37643/In a recent YoungMD Connect virtual mentorship session, DiAnne Davis, MD, FAAD, a dermatologist based in Dallas, discussed her journey from patient to dermatologist, the influence of mentorship, and her commitment to advancing safe, effective cosmetic procedures for patients with skin of color.The ESOP Model: An Alternative to PE for Dermatology Practices
https://practicaldermatology.com/issues/september-2025/the-esop-model-an-alternative-to-pe-for-dermatology-practices/37637/Not all practice models are as simple as private practice vs private equity. At Ada West Dermatology in Boise, Idaho, we’ve adopted a somewhat uncommon business model called an employee stock ownership plan (ESOP) and it’s worked very well for us.Cutaneous Manifestations Associated with Nemolizumab
https://practicaldermatology.com/issues/september-2025/cutaneous-manifestations-associated-with-nemolizumab/37628/In the 2025 study by Sasaki et al entitled “Clinical characteristics and risk factors for cutaneous manifestations associated with nemolizumab in atopic dermatitis: a multicenter retrospective study in Japan,” nemolizumab-induced cutaneous eruptions were found to be relatively common, typically occu